

X-Linked Adrenoleukodystrophy Testing

X-linked adrenoleukodystrophy (X-ALD) is a rare X-linked metabolic disorder caused by variants in the *ABCD1* gene that cause a deficiency in adrenoleukodystrophy protein (ALDP) and subsequent accumulation of very long-chain fatty acids (VLCFAs). VLCFA accumulation occurs in plasma and all tissue types, but primarily affects the adrenal cortex and white matter of the brain and spinal cord, resulting in a range of clinical outcomes.

Adrenal insufficiency may be the initial presentation of X-ALD, and 21-hydroxylase antibody testing may confirm or exclude an autoimmune etiology. In X-ALD, 21-hydroxylase antibody testing results will be normal; therefore, males with adrenal insufficiency and normal 21-hydroxylase antibody testing should be tested for X-ALD (VLCFA profile).

Testing Strategy

Diagnostic Testing

- VLCFA and branched-chain fatty acid (BCFA) profile is the first-line test for an individual with suspected X-ALD or adrenomyeloneuropathy
- Molecular testing (*ABCD1*) is recommended for diagnostic confirmation in individuals with clinical and/or biochemical presentation of X-ALD

Disease Overview

Incidence

1/14,700 live births¹

Genetics

Gene

ABCD1

Structure

ABCD1 gene, contains 10 exons²

Inheritance

X-linked

Penetrance

Neurologic symptoms are present in nearly 100% of males by adulthood.

Tests to Consider

See [Testing Strategy](#)

[Very Long-Chain and Branched-Chain Fatty Acids Profile 2004250](#)

Method: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

- Biochemical test to measure concentration of very long-chain fatty acids (VLCFAs) C22-C26, pristanic acid, and phytanic acid
- Initial test to screen for disorders of peroxisomal biogenesis and/or function, including X-ALD and Zellweger syndrome
- Confirmatory test for abnormal newborn screening suggestive of X-ALD

[Adrenoleukodystrophy, X-Linked \(ABCD1\) Sequencing and Deletion/Duplication 2011906](#)

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

- Preferred molecular test to:
 - Confirm diagnosis of X-ALD following abnormal results from VLCFA profile test
 - Determine carrier status in females when familial variant is unknown
- Detects 99% of pathogenic variants

Related Tests

[Familial Mutation, Targeted Sequencing 2001961](#)

Method: Polymerase Chain Reaction/Sequencing

Useful when a pathogenic familial variant identifiable by sequencing is known

[Deletion/Duplication Analysis by MLPA 3003144](#)

Method: Multiplex Ligation-dependent Probe Amplification

- Useful when a large familial *ABCD1* gene deletion/duplication is known
- Useful for individuals without an identifiable *ABCD1* gene variant by sequence analysis



Variants

- Most are specific to a particular family (“private variants”)
- ~4-19% of individuals with X-ALD have a de novo variant³

For more information on the disease including testing strategy, disease overview, and genetics, visit the [X-Linked Adrenoleukodystrophy](#) topic in ARUP Consult.

Test Interpretation

Biochemical testing (VLCFAs and BCFAs)

- Elevated VLCFAs in males
- ~85% of heterozygous female carriers will have elevated VLCFAs³

Molecular testing (*ABCD1*)

Sensitivity/Specificity

- Clinical sensitivity
 - Sequencing of *ABCD1*: ~97%⁴
 - Deletion/duplication of *ABCD1*: ~3%⁴
- Analytical sensitivity/specificity: 99%

Results

- Positive
 - Pathogenic variant detected
 - Confirms X-ALD in males and carrier status in females
- Negative
 - No variant detected
 - X-ALD is less likely but not excluded
- Inconclusive: variants of unknown clinical significance may be identified

Limitations

- Exons 7-10 are not evaluated by deletion/duplication analysis due to the presence of pseudogenes
- Breakpoints of large deletions/duplications will not be determined
- Diagnostic errors can occur due to rare sequence variations
- Variants in genes other than *ABCD1*, regulatory region variants, and deep intronic variants are not evaluated

References

1. Huffnagel IC, Dijkgraaf MGW, Janssens GE, et al. [Disease progression in women with X-linked adrenoleukodystrophy is slow](#). Orphanet J Rare Dis. 2019;14(1):30. PubMed
2. Kemp S, Berger J, Aubourg P. [X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects](#). Biochim Biophys Acta. 2012;1822(9):1465-1474. PubMed
3. Wiesinger C, Eichler FS, Berger J. [The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis](#). Appl Clin Genet. 2015;8:109-121. PubMed
4. Raymond GV, Moser AB, Fatemi A. [X-linked adrenoleukodystrophy](#). In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews, University of Washington; 1993-2021. [Last update: Feb 2018; Accessed: Jun 2020]



Additional Resources

Bornstein SR, Allolio B, Arlt W, et al. [Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline](#). J Clin Endocrinol Metab. 2016;101(2):364-389. PubMed

Related Information

[X-Linked Adrenoleukodystrophy](#)

ARUP Laboratories is a nonprofit enterprise of the University of Utah and its Department of Pathology. 500 Chipeta Way, Salt Lake City, UT 84108
(800) 522-2787 | (801) 583-2787 | [aruplab.com](#) | [arupconsult.com](#)
Content Review May 2019 | Last Update February 2021

© 2021 ARUP Laboratories. All Rights Reserved.

Client Services - (800) 522-2787

